01—Abstract
Summary
Summary of the 10-Q filed August 5, 2026. Cited figures are marked; the original filing is the authoritative source.
Cencora, Inc. (COR) reported strong revenue growth for the nine months ended June 30, 2026, with a 4.8% increase to $249.0 billiona, driven by solid performance in both its U.S. and International Healthcare Solutions segments.
The company saw significant growth in sales of GLP-1 class products for diabetes and weight loss, contributing to a 4.3% rise in U.S. Healthcare Solutions revenue. International Healthcare Solutions also experienced robust growth, primarily from its European distribution business. Profitability also showed improvement, with gross profit increasing by 20.4% year-over-year to $10.3 billionb, bolstered by strategic acquisitions, including OneOncology and RCA, and increased pharmaceutical sales.
Despite rising operating expenses, largely due to acquisition integration costs, Cencora's segment operating income grew by 11.4%c. The company continues to manage its debt effectively, with a strong liquidity position supported by its credit facilities, and remains committed to returning value to shareholders through share repurchases and dividends.
02—Key points
Key Highlights
- Revenue increased by 4.8% to $249.0 billion for the nine months ended June 30, 2026, driven by growth in both U.S. and International Healthcare Solutions segments.
- Gross profit increased by 20.4% to $10.3 billion, aided by acquisitions and increased pharmaceutical sales, including a significant contribution from GLP-1 products.
- Total segment operating income grew by 11.4% year-over-year, demonstrating improved profitability despite increased operating expenses.
- The company made significant progress in integrating major acquisitions, notably OneOncology and RCA, which contributed positively to revenue and gross profit.
- Cencora's balance sheet shows robust asset growth, with total assets reaching $83.8 billion, an increase driven by goodwill and intangible assets from acquisitions.
- Debt levels increased, largely due to financing the OneOncology acquisition, but the company maintains access to significant credit facilities, ensuring strong liquidity.
- The company continues to prioritize shareholder returns, with active share repurchase programs and a consistent quarterly dividend payment.
03—Questions
Frequently Asked Questions
What were the main drivers of Cencora's revenue growth in the first nine months of fiscal year 2026?
Cencora's revenue growth was primarily driven by increases in both its U.S. Healthcare Solutions and International Healthcare Solutions segments. Specifically, strong unit volume growth, increased sales of specialty products, and a significant rise in sales of GLP-1 class products for diabetes and weight loss contributed to the overall increase. The European distribution business also showed robust growth.
How have recent acquisitions impacted Cencora's financial performance?
Recent acquisitions, particularly OneOncology (completed February 2026) and RCA (completed January 2025), have had a substantial positive impact on Cencora's financial performance. These acquisitions have driven revenue growth, increased gross profit, and contributed to overall segment operating income growth. The integration of these businesses is a key focus for the company.
What is the status of Cencora's opioid litigation and its financial impact?
Cencora has accrued a litigation liability of $4.2 billion related to opioid litigation, which is expected to be paid over 13 years. The company has settled a substantial majority of opioid lawsuits filed by state and local governmental entities through a Distributor Settlement Agreement. While the accrued liability is significant, the company has processes in place for managing these payments and expects its ongoing operations and cash flows to be sufficient to cover these obligations.
How is Cencora managing its debt and liquidity?
Cencora's total debt increased significantly due to financing the OneOncology acquisition, reaching $11.7 billion. However, the company maintains a strong liquidity position with substantial availability under its multi-currency revolving credit facility and receivables securitization facility. These facilities provide flexibility for working capital needs and other financing requirements.
04—Continue